Review of studies reporting actual prices for medicines

References

• Vogler S, Zimmermann N, Babar ZU. Price comparison of high-cost originator medicines in European countries. Expert Rev Pharm Out. 2017 Apr;17(2):221–230.
   Google Scholar
• Scalo JF, Rascati KL. Trends and issues in oncology costs [Review]. Expert Rev Pharm Out. 2014 Feb;14(1):35–44.
   Google Scholar
• Luiza VL, Chaves LA, Silva RM, et al. Pharmaceutical policies: effects of cap and co-payment on rational use of medicines [Review]. Cochrane Database Syst Rev. 2015 May;08(5):CD007017.
   Google Scholar
• Vogler S, Habl C, Bogut M, et al. Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European union member states. Croat Med J. 2011 Apr 15;52(2):183–197.
   PubMed Web of Science ®Google Scholar
• Vogler S, Zimmermann N, Habl C. Understanding the components of pharmaceutical expenditure—overview of pharmaceutical policies influencing expenditure across European countries. GaBI J. 2013;2(4):178–187.
   Google Scholar
• World Health Organisation. Measuring medicine prices, availability, affordability and price components; 2008 [cited 2018 Mar 15]. Available from: http://www.who.int/medicines/areas/access/OMS_Medicine_prices.pdf?ua=1
   Google Scholar
• Toumi M, Remuzat C, Vataire A, et al. External reference pricing of medicinal products: simulation-based considerations for cross-county coordination; 2013 [cited 2018 Mar 15]. Available from: http://ec.europa.eu/health/healthcare/docs/erp_reimbursement_medicinal_products_en.pdf
   Google Scholar
• Vogler S, Lepenschütz L, Schneider P, et al. Study on enhanced cross-country coordination in the area of pharmaceutical product pricing; 2015 [cited 2018 Feb 8]. Available from: http://ec.europa.eu/health/sites/health/files/systems_performance_assessment/docs/pharmaproductpricing_frep_en.pdf
   Google Scholar
• World Health Organisation Regional office for Europe. Access to new medicines in Europe: technical review of policy initiatives and opportunities for collaboration and research; 2015 [cited 2018 Mar 15]. Available from: https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&uact=8&ved=0ahUKEwjd5omY6L7aAhUL-qQKHT7NCIgQFggnMAA&url=http%3A%2F%2Fapps.who.int%2Fmedicinedocs%2Fdocuments%2Fs21793en%2Fs21793en.pdf&usg=AOvVaw2xBzgIT-m2MzQZFB3PLyJg
   Google Scholar
• Espin J, Rovira J, de Labry A Working paper 1: external price referencing – review series on pharmaceutical pricing policies and interventions. Geneva: World Health Organization and Health Action International; 2011.
   Google Scholar
• WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies. Glossary of pharmaceutical terms. Viena, Austria; 2016. [cited 2017 December 9]. Available from: http://whocc.goeg.at/Literaturliste/Dokumente/MethodologyTemplate/Glossary_Update2016_final.pdf
   Google Scholar
• Leopold C, Mantel-Teeuwisse AK, Seyfang L, et al. Impact of external price referencing on medicine prices - a price comparison among 14 European countries. South Med Rev. 2012 Dec;5(2):34–41.
   PubMedGoogle Scholar
• Folino-Gallo P, Muscolo L, Vogler S, et al. PHIS Glossary: glossary for pharmaceutical policies/systems developed in the pharmaceutical health information system (PHIS) Project; 2011 [cited 2018 Mar 15]. Available from: http://whocc.goeg.at/Glossary/PreferredTerms/External%20price%20referencing
   Google Scholar
• Mycka JM, Dellamano R, Kolassa EM, et al. Good research practices for measuring drug costs in cost effectiveness analyses: an industry perspective: the ISPOR Drug Cost Task Force report–part V. Value Health. 2010 Jan-Feb;13(1):25–27.
   PubMed Web of Science ®Google Scholar
• Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007 Oct 16;4(10):e297.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009 Jul 21;6(7):e1000100.
   PubMed Web of Science ®Google Scholar
• International Drug Price Indicator Guide [ cited 2017 December 9]. Available from: https://www.msh.org/resources/international-medical-products-price-guide?keywords=international%20drug%20price%20indicator
   Google Scholar
• Vogler S, Zimmermann N, Habl C, et al. Discounts and rebates granted to public payers for medicines in European countries. South Med Rev. 2012 Jul;5(1):38–46.
   PubMedGoogle Scholar
• Morgan SG, Vogler S, Wagner AK. Payers’ experiences with confidential pharmaceutical price discounts: A survey of public and statutory health systems in North America, Europe, and Australasia. Health Policy. 2017 Apr;121(4):354–362.
   PubMed Web of Science ®Google Scholar
• Theidel U, von der Schulenburg JM. Benefit assessment in Germany: implications for price discounts. Health Econ Rev. 2016 Dec;6(1):33.
   PubMed Web of Science ®Google Scholar
• Puig-Junoy J. Do higher-priced generic medicines enjoy a competitive advantage under reference pricing? [Research support, Non-U.S. Gov’t]. Appl Health Econ Health Pol. 2012 Nov 1;10(6):441–451.
   PubMedGoogle Scholar
• Vogler S, Zimmermann N, Habl C, et al. The role of discounts and loss leaders in medicine procurement in Austrian hospitals - a primary survey of official and actual medicine prices. Cost Eff Resour Alloc. 2013 Jul 4;11(1):15.
   PubMedGoogle Scholar
• Sharma A, Rorden L, Ewen M, et al. Evaluating availability and price of essential medicines in Boston area (Massachusetts, USA) using WHO/HAI methodology. J Pharm Policy Pract. 2016;9:12.
   PubMedGoogle Scholar
• Arora S, Sood N, Terp S, et al. The price may not be right: the value of comparison shopping for prescription drugs. Am J Manag Care. 2017 Jul;23(7):410–415.
   PubMed Web of Science ®Google Scholar
• Freed GL, Cowan AE, Gregory S, et al. Variation in provider vaccine purchase prices and payer reimbursement. Pediatrics. 2009 Dec;124(Suppl 5):S459–65.
   PubMedGoogle Scholar
• Robinson JC, Whaley CM, Brown TT. Association of reference pricing with drug selection and spending. N Engl J Med. 2017 Aug 17;377(7):658–665.
   PubMed Web of Science ®Google Scholar
• Samal S, Swain TR. Pricing and components analysis of some key essential pediatric medicine in Odisha state. Indian J Pharmacol. 2017 Jan-Feb;49(1):89–92.
   PubMed Web of Science ®Google Scholar
• Mouly S, Charlemagne A, Lejeunne P, et al. Therapeutic management of uncomplicated gastroesophageal reflux disease in france in 2005: potential cost savings of omeprazole substitution. Curr Ther Res Clin Exp. 2009 Aug;70(4):282–298.
   PubMed Web of Science ®Google Scholar
• Roggeri A, Micheletto C, Roggeri DP. Outcomes and costs of treating chronic obstructive pulmonary disease with inhaled fixed combinations: the Italian perspective of the PATHOS study. Int J Chron Obstruct Pulmon Dis. 2014;9:569–576.
   PubMed Web of Science ®Google Scholar
• Schafer HH, Scheunert U. Costs of current antihypertensive therapy in Switzerland: an economic evaluation of 3,489 patients in primary care [Research Support, Non-U.S. Gov’t]. Swiss Med Wkly. 2013 Oct 25;143:w13854.
   PubMedGoogle Scholar
• Anson A, Ramay B, de Esparza AR, et al. Availability, prices and affordability of the world health organization’s essential medicines for children in Guatemala [Research Support, N.I.H., Extramural]. Global Health. 2012 Jul;2(8):22.
   Web of Science ®Google Scholar
• Wang X, Fang Y, Yang S, et al. Access to paediatric essential medicines: a survey of prices, availability, affordability and price components in Shaanxi Province, China. PLoS One. 2014;9(3):e90365.
   PubMed Web of Science ®Google Scholar
• Jiang M, Yang S, Yan K, et al. Measuring access to medicines: a survey of prices, availability and affordability in Shaanxi province of China [Research support, Non-U.S. Gov’t]. PLoS One. 2013;8(8):e70836.
   PubMed Web of Science ®Google Scholar
• Thai LP, Vitry AI, Moss JR. Discounting of medicines in Australian community pharmacies. Aust Health Rev. 2014 Nov;38(5):517–522.
   PubMed Web of Science ®Google Scholar
• Chokshi M, Farooqui HH, Selvaraj S, et al. A cross-sectional survey of the models in Bihar and Tamil Nadu, India for pooled procurement of medicines. WHO South East Asia J Public Health. 2015 Jan-Jun;4(1):78–85.
   PubMedGoogle Scholar
• Kim SH, Ryu YJ, Cho NE, et al. Prescription drug price paradox: cost analysis of canadian online pharmacies versus US medicare beneficiaries for the top 100 drugs. Clin Drug Investig. 2017 Oct;37(10):957–963.
   PubMed Web of Science ®Google Scholar
• Schlenker MB, Trope GE, Buys YM. Comparison of United States and canadian glaucoma medication costs and price change from 2006 to 2013. J Ophthalmol. 2015;2015:547960.
   PubMed Web of Science ®Google Scholar
• Zaprutko T, Kopciuch D, Kus K, et al. Affordability of medicines in the European Union. PLoS One. 2017;12(2):e0172753.
   PubMed Web of Science ®Google Scholar
• de Bruijn W, Ibanez C, Frisk P, et al. Introduction and utilization of high priced hcv medicines across Europe; implications for the future. Front Pharmacol. 2016;7:197.
   PubMed Web of Science ®Google Scholar
• van Harten WH, Wind A, de Paoli P, Saghatchian M, Oberst S. Actual costs of cancer drugs in 15 European countries. The Lancet Oncology. 2016;17(1):18-20.
   PubMed Web of Science ®Google Scholar
• Palafox B, Patouillard E, Tougher S, et al. Prices and mark-ups on antimalarials: evidence from nationally representative studies in six malaria-endemic countries [Research support, Non-U.S. Gov’t]. Health Policy Plan. 2016 Mar;31(2):148–160.
   PubMed Web of Science ®Google Scholar
• Godman B, De Bruyn K, Miranda J, et al. Generic atypical antipsychotic drugs in Belgium: their influence and implications. J Comp Eff Res. 2013 Nov;2(6):551–561.
   PubMed Web of Science ®Google Scholar
• Garuoliene K, Godman B, Gulbinovic J, et al. European countries with small populations can obtain low prices for drugs: lithuania as a case history. Expert Rev Pharm Out. 2011 Jun;11(3):343–349.
   Google Scholar
• Wladysiuk M, Araszkiewicz A, Godman B, et al. Influence of patient co-payments on atypical antipsychotic choice in Poland: implications once generic atypicals are available. Appl Health Econ Health Policy. 2011 Mar 01;9(2):101–110.
   PubMedGoogle Scholar
• Johnson JT, Neill KK, Davis DA. Five-year examination of utilization and drug cost outcomes associated with benefit design changes including reference pricing for proton pump inhibitors in a state employee health plan. J Manag Care Pharm. 2011 Apr;17(3):200–212.
   PubMed Web of Science ®Google Scholar
• Jo JS, Kim YM, Paek KW, et al. Factors contributing to increases in prescription drug expenditures borne by national health insurance in South Korea. Yonsei Med J. 2016 Jul;57(4):1016–1021.
   PubMed Web of Science ®Google Scholar
• Yadav P, Cohen JL, Alphs S, et al. Trends in availability and prices of subsidized ACT over the first year of the AMFm: evidence from remote regions of Tanzania [Research support, Non-U.S. Gov’t]. Malaria J. 2012 Aug;28(11):299.
   Web of Science ®Google Scholar
• Atzinger CB, Guo JJ. Biologic disease-modifying antirheumatic drugs in a national, privately insured population: utilization, expenditures, and price trends. Am Health Drug Benefits. 2017 Feb;10(1):27–36.
   PubMed Web of Science ®Google Scholar
• Rosenberg ME, Rosenberg SP. Changes in retail prices of prescription dermatologic drugs from 2009 to 2015. JAMA Dermatol. 2016 Feb;152(2):158–163. PubMed PMID: 26606197; eng.
   PubMed Web of Science ®Google Scholar
• Gordon N, Stemmer SM, Greenberg D, et al. Trajectories of injectable cancer drug costs after launch in the United States. J Clin Oncol. 2017;36(4):319-325.
   Web of Science ®Google Scholar
• World Health Organisation. WHO guideline on country pharmaceutical pricing policies; 2015 [cited 2018 Mar 19]. Available from: http://apps.who.int/medicinedocs/documents/s21016en/s21016en.pdf
   Google Scholar
• Mardetko N, Kos M. Introduction of therapeutic reference pricing in Slovenia and its economic consequences. Eur J Health Econ. 2017;19(4):571–584.
   PubMed Web of Science ®Google Scholar
• Schneeweiss S. Reference drug programs: effectiveness and policy implications. Health Policy. 2007 Apr;81(1):17–28.
   PubMed Web of Science ®Google Scholar
• Galizzi MM, Ghislandi S, Miraldo M. Effects of reference pricing in pharmaceutical markets: a review. Pharmacoeconomics. 2011 Jan;29(1):17–33.
   PubMed Web of Science ®Google Scholar
• Mardetko N, Kos M. Patients’ knowledge and attitude towards therapeutic reference pricing system in Slovenia. Int J Clin Pharm. 2016 Oct;38(5):1301–1310.
   PubMed Web of Science ®Google Scholar
• De Block M. The difficulty of comparing drug prices between countries. Lancet Oncol. 2016;17:4.
   Web of Science ®Google Scholar
• Pauwels K, Huys I, Vogler S, et al. Managed entry agreements for oncology drugs: lessons from the European experience to inform the future. Front Pharmacol. 2017;8:171.
   PubMed Web of Science ®Google Scholar
• Ferrario A, Kanavos P. Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden [Comparative study]. Soc sci med. 2015 Jan;124:39–47. PubMed PMID: 25461860; eng.
   PubMed Web of Science ®Google Scholar
• Vogler S, Paris V, Ferrario A, et al. How can pricing and reimbursement policies improve affordable access to medicines? lessons learned from European countries [Review]. Appl Health Econ Health Policy. 2017 Jun;15(3):307–321.
   PubMed Web of Science ®Google Scholar